Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JPGXX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
igG (8)-m- (b-PEG12)-VC-MMAE
|
|||||
| Synonyms |
IgG (8)-m- (b-PEG12)-VC-MMAE
Click to Show/Hide
|
|||||
| Organization |
University of Tours, University of Orléans.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
IgG (8)-m- (b-PEG12)-VC-MMAE
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.029 nM | High HER2 expression (HER2+++) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 100 nM | Low HER2 expression (HER2+) | ||
| Method Description |
IC50 (in nM) cell-based assays of tested entities on breast cancer cell lines MDA-MB-231 (HER2-low)
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells (HER2 low) | CVCL_0062 | ||
References